Pediatrics
Latest news
375 articles · 20 / page
Weight Trajectories Among Youths Following Residential Relocation
This study explores how changes in residential environments affect childhood BMI, focusing on air pollution, built environment, and socioeconomic factors across cohorts in the Netherlands, Sweden, and Czech Republic.
Community Health Workers Halt Decline in Quality of Life During Transition to Adult Care for Young Adults With Sickle Cell Disease
A multicenter randomized trial found that community health worker support produced modest but durable improvements in health-related quality of life for young adults with sickle cell disease during transition to adult care, whereas a mobile
Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use
A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipola
Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice
A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with se
CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial
In the ML‑DS 2018 trial, substituting reduced‑intensity induction with CPX‑351 led to lower 24‑month event‑free survival (69% vs 90%) despite excellent overall survival and minimal treatment‑related mortality; MRD by GATA1 NGS, trisomy 8 an
Is the Gut Microbiome Really a Key to Understanding Autism?
A critical review highlights serious flaws in research linking gut microbiome to autism, questioning its causal role and urging more rigorous studies or reconsideration of this research path.
Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–
Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns
First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegr
Very Early Neonatal ART Enables ART‑Free HIV‑1 Remission in Some Children: Clinical Insights from IMPAACT P1115
IMPAACT P1115 shows that initiating combination ART within 48 hours of birth can enable sustained ART‑free HIV‑1 remission for 48+ weeks in a subset of children with in‑utero infection, but careful selection, close monitoring and standardiz
Genomic Newborn Screening Is Feasible, Highly Acceptable and Clinically Actionable: Lessons from the BabyScreen+ Cohort
BabyScreen+ shows clinically accredited whole‑genome sequencing from dried blood spots can be integrated into newborn screening at scale: 1.6% of 1,000 babies had high‑chance actionable findings, median return 13 days, strong parental accep
Atosiban Did Not Improve Neonatal Outcomes for Threatened Preterm Birth at 30–34 Weeks: Results from the Multicentre APOSTEL 8 Trial
In the APOSTEL 8 randomized trial, intravenous atosiban did not reduce a composite of perinatal mortality and severe neonatal morbidity versus placebo for threatened preterm birth at 30+0–33+6 weeks.
Nirsevimab Halves RSV Bronchiolitis Risk in Infants — High Effectiveness Sustained Despite Emergent RSV‑B Mutations
A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.
Nirsevimab Cuts RSV Lower Respiratory Infections in Infants Without Replacing Other Viruses: Post‑hoc Analysis of the Phase 3 MELODY Trial
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
Nirsevimab in Chile’s First National RSV Campaign: 76% Reduction in RSV Hospitalisations and 85% Fewer ICU Admissions in Infants
A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to preven
Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required
A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12
Widespread Nirsevimab and Maternal RSV Vaccination Linked to Large Drop in Infant Hospitalizations in First Full Season
Real-world surveillance from 2024–2025 shows substantial reductions in RSV-associated hospitalizations among infants after broad availability of maternal RSV vaccination and nirsevimab, with effectiveness estimates approximating those from
Screening Children and Young Adults for Familial Hypercholesterolemia: Clinically Helpful but Not Cost‑Effective
A modeling study found that sequential population screening for familial hypercholesterolemia (FH) at ages 10 or 18 is clinically effective but not cost‑effective versus usual care, unless follow-up monitoring and lifestyle interventions fo
Less Sitting, More Sleep and MVPA Linked to Better Glycaemic Stability in Children with Type 1 Diabetes: A 2‑Year Compositional Analysis
A longitudinal compositional analysis of 83 children with type 1 diabetes found that reallocating daily time away from sedentary behaviour toward sleep or moderate‑to‑vigorous physical activity (MVPA) was associated with lower HbA1c and int
Balance, Not Bedrest: Daily Movement Patterns Linked to Faster Symptom Recovery After Pediatric Concussion
Compositional analysis of the PedCARE cohort suggests that an early period of relative rest combined with above-average light and moderate-to-vigorous activity over the first two weeks is associated with lower postconcussion symptom burden
FDA Approves Linzess for Pediatric IBS with Constipation: A New Hope for Children
The FDA has approved linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) in children 7 and older, marking the first official treatment option for pediatric IBS-C.
Browse by specialty
Open language-specific specialty feeds and department pages.